Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database.
Bhutiani N, Yousef MMG, Yousef A, Zeineddine M, Knafl M, Ratliff O, Fernando UP, Turin A, Zeineddine FA, Jin J, Alfaro-Munoz K, Goldstein D, Chang GJ, Kopetz S, Shen JP, Uppal A. Bhutiani N, et al. Among authors: alfaro munoz k. JCO Clin Cancer Inform. 2024 May;8:e2300219. doi: 10.1200/CCI.23.00219. JCO Clin Cancer Inform. 2024. PMID: 38759125 Free article.
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Yousef A, et al. Among authors: alfaro munoz k. NPJ Precis Oncol. 2024 Feb 3;8(1):27. doi: 10.1038/s41698-024-00505-0. NPJ Precis Oncol. 2024. PMID: 38310130 Free PMC article.
Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.
Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Yousef A, et al. Among authors: alfaro munoz k. Res Sq [Preprint]. 2023 Aug 10:rs.3.rs-3195257. doi: 10.21203/rs.3.rs-3195257/v1. Res Sq. 2023. PMID: 37609177 Free PMC article. Updated. Preprint.
A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.
Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. Ferguson SD, et al. Among authors: alfaro munoz k. Neurooncol Adv. 2020 Oct 31;3(1):vdaa146. doi: 10.1093/noajnl/vdaa146. eCollection 2021 Jan-Dec. Neurooncol Adv. 2020. PMID: 33426529 Free PMC article.
iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium.
Bakas S, Ormond DR, Alfaro-Munoz KD, Smits M, Cooper LAD, Verhaak R, Poisson LM. Bakas S, et al. Among authors: alfaro munoz kd. Neuro Oncol. 2020 Oct 14;22(10):1545-1546. doi: 10.1093/neuonc/noaa160. Neuro Oncol. 2020. PMID: 32644158 Free PMC article. No abstract available.
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. de Groot J, et al. Among authors: alfaro munoz k. Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185. Neuro Oncol. 2020. PMID: 31755915 Free PMC article.
16 results